'We play to win': As­traZeneca de­tails first re­sults for oral GLP-1 and broad­er obe­si­ty am­bi­tions

SAN AN­TO­NIO — Well be­hind No­vo Nordisk and Eli Lil­ly in the obe­si­ty race, As­traZeneca came to this year’s Obe­si­ty­Week with three as­sets in hand …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA